Phase 3 trials show orexin agonist oveporexton improves cognition, sleep, and daily function in narcolepsy type 1
By
Megan Brooks
Summary
Phase 3 clinical trials show that the investigational drug oveporexton (TAK-861), an oral orexin receptor 2 agonist developed by Takeda, improves not only wakefulness and cataplexy control in patients with narcolepsy type 1 (NT1), but also enhances cognitive performance, daily functioning, work productivity, and nighttime sleep. The results reinforce the understanding that narcolepsy is a 24-hour disease requiring comprehensive treatment beyond daytime sleepiness.
Source
Twitter / XPhase 3 trials show orexin agonist oveporexton improves cognition, sleep, and daily function in narcolepsy type 1mdsc.peKey quotes
· 2 pulledNarcolepsy is a 24-hour disease
The oral orexin receptor 2 agonist improved cognitive performance, daily functioning, and work productivity in addition to wakefulness and cataplexy control
You might also wanna read
Decades of sleep physiology research at University of Toronto leads to new sleep apnea drug showing promise in Phase 3 trial
A University of Toronto professor's decades-long research on the physiology of sleep and breathing has led to a new drug treatment for sleep
temertymedicine.utoronto.ca·29d ago
Elemind: Wearable Neurotechnology Device for On-Demand Sleep Enhancement
Elemind is a wearable neurotechnology device designed to help users achieve faster sleep on-demand. The product uses neurotechnology to modu
Product Hunt·8mo ago
GLP-1 Therapy Reduces Migraine Frequency by More Than Half in Obesity Patients
A study from the University of Naples found that liraglutide, a GLP-1 receptor agonist typically used for diabetes and obesity, significantl
medlink.com·6mo ago
GLP-1 Medications Show Promise for Treating Addiction Through Brain Reward Pathways
The article explores the emerging potential of GLP-1 medications like Ozempic to treat various addictions beyond their original diabetes and
newyorker.com·4mo agohttps://www.cell.com/cell/fulltext/S0092-8674(26)00287-4
Phase 3 Trial of Ecopipam for Tourette Syndrome: Safety and Efficacy Evaluation
This Phase 3 randomized clinical trial evaluates the safety and maintenance of effect of ecopipam, a selective dopamine D1 receptor antagoni
doi.org·15d ago